Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis
August 13, 2024 08:00 ET
|
Biomed Valley Discoveries, Inc.
Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
February 25, 2020 16:03 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company preparing to initiate a...
Kura Oncology Announces Transition of Chief Medical Officer
January 23, 2020 16:05 ET
|
Kura Oncology, Inc.
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
January 09, 2020 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
January 06, 2020 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Present at Stifel Healthcare Conference
November 12, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
November 06, 2019 09:06 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 05, 2019 16:05 ET
|
Kura Oncology, Inc.
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted...
Kura Oncology to Participate in Two Upcoming Investor Conferences
August 29, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
August 12, 2019 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...